Physician profile
Susan Edlibi
NPI 1255825501
$6,931.48
in general payments reported to CMS, 2019-2025
21 companies · $2,288 in 2025
The $2,288 reported for 2025 was more than what 75% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $827 · 2023: $2,539 · 2024: $1,277 · 2025: $2,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,209 · Grant: $800 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,209.02 |
| Grant | $800.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,871.45 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,678.73 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $761.59 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $745.20 | 2022-2025 | Nucala, Shingrix |
| Csl Behring | $427.90 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Genentech USA, INC. | $289.23 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $207.69 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $190.28 | 2024-2025 | Cuvitru, Eohilia |
| Genentech, INC. | $118.16 | 2023 | Xolair |
| Blueprint Medicines Corporation | $100.90 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Pfizer INC. | $94.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $85.51 | 2025 | |
| Octapharma USA, INC. | $79.65 | 2024-2025 | Cutaquig, Panzyga |
| Biocryst US Sales Co., LLC | $53.89 | 2025 | Orladeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.66 | 2024-2025 | Tezspire |
| Incyte Corporation | $24.85 | 2025 | Opzelura |
| Lilly USA, LLC | $24.28 | 2025 | Ebglyss |
| Phadia US INC. | $19.07 | 2025 | Immunocap |
| Alk-Abello, INC | $18.01 | 2025 | Alternaria Tenuis, Standardized Mite D. Farinae, Timothy, Standardized |
| Hospira, INC. | $14.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Edlibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.